6T40 Stock Overview
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Trevena, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.33 |
| 52 Week High | US$3.00 |
| 52 Week Low | US$0.29 |
| Beta | 1.1 |
| 1 Month Change | -16.67% |
| 3 Month Change | -42.27% |
| 1 Year Change | -41.76% |
| 3 Year Change | -99.08% |
| 5 Year Change | -98.99% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6T40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -26.4% | -0.2% | 0.5% |
| 1Y | -41.8% | -22.8% | 1.3% |
Return vs Industry: 6T40 underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 6T40 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 6T40 volatility | |
|---|---|
| 6T40 Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6T40's share price has been volatile over the past 3 months.
Volatility Over Time: 6T40's weekly volatility has decreased from 39% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Carrie Bourdow | www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc. Fundamentals Summary
| 6T40 fundamental statistics | |
|---|---|
| Market cap | €6.51m |
| Earnings (TTM) | -€37.56m |
| Revenue (TTM) | €2.91m |
2.4x
P/S Ratio-0.2x
P/E RatioIs 6T40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6T40 income statement (TTM) | |
|---|---|
| Revenue | US$3.13m |
| Cost of Revenue | US$1.67m |
| Gross Profit | US$1.46m |
| Other Expenses | US$41.74m |
| Earnings | -US$40.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | 46.56% |
| Net Profit Margin | -1,289.25% |
| Debt/Equity Ratio | -402.4% |
How did 6T40 perform over the long term?
See historical performance and comparison